MARKET

INM

INM

InMed Pharmaceuticals Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.820
-0.090
-3.09%
Closed 16:00 04/22 EDT
OPEN
2.950
PREV CLOSE
2.910
HIGH
2.950
LOW
2.750
VOLUME
70.34K
TURNOVER
--
52 WEEK HIGH
10.43
52 WEEK LOW
2.650
MARKET CAP
21.55M
P/E (TTM)
-1.9024
1D
5D
1M
3M
1Y
5Y
The Daily Biotech Pulse: Q1 Beat From Johnson & Johnson, KalVista Study Placed On Hold, European Label Expansion For GW Pharma's Epidiolex
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 15)
Benzinga · 2d ago
WRAPUP 1-Asia's rising coronavirus cases a worry as vaccine doubts cloud campaigns
reuters.com · 04/08 08:48
Ontario Lottery and Gaming Corporation - MidDay lottery winning numbers - March 17, 2021
TORONTO, March 17, 2021 /CNW/ - Wednesday 17/03/2021PICK-2: 7 0 PICK-3: 7 8 5 PICK-4: 1 9 4 5 ENCORE: 6681006 DAILY KENO 1, 5, 8, 10, 14, 16, 22, 34, 35, 40, 44, 45, 49, 50, 52, 56, 57, 59, 64, 69.SOURCE OLG WinnersView original content: http://www.
CNW Group · 03/17 19:49
InvestorNewsBreaks - InMed Pharmaceuticals Inc. (NASDAQ: INM) (TSX: IN) Completes $4.5M PIPE Transaction
Mar 15, 2021 (Investor Brand Network via COMTEX) -- InMed Pharmaceuticals (NASDAQ: INM) (TSX: IN), a clinical-stage pharmaceutical company developing...
Investor Brand Network · 03/15 13:46
BRIEF-Inmed Pharmaceuticals Inc Files Prospectus Relates To Offering And Resale By Selling Shareholders Of Up To 1.7 Mln Of Common Shares
reuters.com · 03/05 21:11
InMed to Present at Virtual Conferences in March 2021
GlobeNewswire · 03/03 23:00
IIROC Trading Halt - TTO.H
26, 2021 /CNW/ - The following issues have been halted by IIROC: Company: Atoro Capital Corp.H All Issues: YesReason: At the Request of the Company Pending NewsHalt Time (ET): 7:49 AM IIROC can make a decision to impose a temporary suspension (halt) of tra...
CNW Group · 02/26 13:00
InMed Announces Closing of US$4.5 Million Private Placement
16, 2021 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (Nasdaq: INM) (TSX: IN), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the clinical development of cannabino...
CNW Group · 02/16 12:30
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of INM. Analyze the recent business situations of InMed Pharmaceuticals Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average INM stock price target is 11.50 with a high estimate of 11.50 and a low estimate of 11.50.
EPS
Institutional Holdings
Institutions: 14
Institutional Holdings: 41.37K
% Owned: 0.54%
Shares Outstanding: 7.64M
TypeInstitutionsShares
Increased
0
0
New
14
41.37K
Decreased
0
0
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
No Data
About INM
InMed Pharmaceuticals Inc. is a pre-clinical-stage biopharmaceutical company. The Company specializes in the research and development of cannabinoid-based therapies combined with drug delivery systems. The Company operates through the segment of research and development of pharmaceutical cannabis based-therapies. The Company is working on two products, which include INM-750, for the treatment of Epidermolysis Bullosa (EB), and INM-085, for the treatment of Glaucoma. The INM-750 is a therapy developed for EB designed specifically to modulate disease activity and to alleviate symptoms. The INM-085 is designed as a dual-action cannabinoid ocular therapy. INM-085 is designed as a topical formulation to be administered directly to the eye. It is working on the development of several cannabinoid-based treatments for multiple diseases, including ocular, dermatology, cancer, inflammation, pain and arthritis disease areas. Its subsidiary is Biogen Sciences Inc. (BSI).

Webull offers kinds of InMed Pharmaceuticals Inc stock information, including NASDAQ:INM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading INM stock methods without spending real money on the virtual paper trading platform.